IDRA 21 CAS 22503-72-6 Pharmaceutical Anabolic Steroids For Health Care Product Additive

Quick Detail:

Description:

IDRA-21 is an ampakine drug derived from benzothiadiazine and a positive allosteric modulator of glutamate AMPA receptors. IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 10-30 times more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine, and produces sustained effects lasting for up to 48 hours after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.

In comparison to the benzoylpiperidine derived ampakine drugs, IDRA-21 was more potent than CX-516, but less potent than CX-546. Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX-series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.

Application:

As an Ampakine, IDRA-21 works by modulating AMPA receptors in the brain. it may prevent AMPA receptor desensitization, specifically IDRA-21 binds to the allosteric site of the AMPA receptor and induce positive modulation, this is sometimes called allosteric activation.

This property enhances long-term potentiation, especially within the hippocampus and may thus have beneficial therapeutic effects. This research could imply that IDRA-21 facilitates treatment of AMPA-related learning disabilities or enhancing intelligence in those without any learning disabilities.

In animal studies, IDRA-21 showed extremely long-lasting nootropic effects in improved learning and memory for up to 48 hours with a single dose. IDRA-21 showed to be up to ten times more powerful than the similar supplement aniracetam.